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Introduction. The objective of the present study was to compare QUANTA Flash dsDNA, a chemiluminescent immunoassay (CIA)
on the BIO-FLASH, a rapid-response chemiluminescent analyzer, to three other anti-dsDNA antibody assays and to Crithidia
luciliae indirect immunofluorescence test (CLIFT). Methods. In the first part of the study, 161 samples, 61 from patients suffering
from systemic lupus erythematosus (SLE) and 100 from a disease control group, were tested by QUANTA Flash dsDNA CIA,
QUANTA Lite dsDNA SC ELISA, BioPlex 2200 multiplex flow immunoassay (MFI), ImmuLisa dsDNA ELISA, and NOVA Lite
CLIFT. A second cohort of 69 SLE patients was then tested by QUANTA Flash dsDNA and CLIFT to expand the study. Results.
The overall qualitative agreements varied between 77.0% (NOVA Lite CLIFT versus QUANTA Lite) and 89.4% (ImmuLisa versus
NOVA Lite CLIFT). The clinical sensitivities for the anti-dsDNA antibody tests varied from 8.2% (NOVA Lite CLIFT) to 54.1%
(QUANTA Lite), while the clinical specificities varied from 88.0% (BioPlex 2200) to 100.0% (NOVA Lite CLIFT). Good correlation
was found between QUANTA Flash dsDNA and NOVA Lite CLIFT. Conclusion. Significant variations among dsDNA methods
were observed. QUANTA Flash dsDNA provides a good combination of sensitivity and specificity for the diagnosis of SLE and
good agreement to CLIFT.
1. Introduction
The detection of anti-dsDNA autoantibodies represents a
hallmark in the diagnosis of systemic lupus erythematosus
(SLE) [1] and these antibodies are part of the classification
criteria for SLE [2, 3]. Additionally, anti-dsDNA antibodies
measured by certain assays have been reported to correlate
with disease activity and lupus nephritis. Despite the fact
that several assay systems have been developed during the
last decades, controversies persist on which assay is the best
test to measure anti-dsDNA antibodies [4, 5]. Although the
Farr assay has been considered the “gold standard” for the
detection of anti-dsDNA antibodies in many laboratories
[4, 6, 7], radioimmunoassays in general have recently been
falling into disuse in routine practice based on several factors,
including the radioactive nature of the assay. Therefore, it
is important to evaluate new fully automated technologies
which have recently become available as viable alternatives to
Farr assay. The objective of the present study was to compare
QUANTA Flash dsDNA, a chemiluminescent immunoassay
(CIA) on the BIO-FLASH, a rapid-response chemilumines-
cent analyzer, to three other anti-dsDNA antibody assays
and to Crithidia luciliae indirect immunofluorescence test
(CLIFT).
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Table 1: Characteristics of the anti-dsDNA antibody assays used in this study.
Characteristic QUANTA FlashdsDNA
QUANTA Lite
dsDNA SC
BioPlex 2200
dsDNA ImmuLisa dsDNA NOVA Lite dsDNA
Manufacturer Inova Diagnostics Inova Diagnostics Bio-Rad ImmcoDiagnostics Inova Diagnostics
Technology CIA ELISA ALBIA ELISA CLIFT
Assay timer 30min 90min 45min 90min 60min
Detection Quantitative Quantitative Quantitative Semi-quantitative Semi-quantitative
Analytical measuring range 9.8–666.9 IU/mL 12.3–1000 IU/mL 1–300 IU/mL 13.6–450 IU/mL N/A
Cut-off value (ranges)
9.8–35 negative
35–45 equivocal
>45 positive
12.3–30 negative
30–75 equivocal
>75 positive
1–5 negative
5–9 indeterminate
>9 positive
13.6–50 negative
50–60 borderline
>60 positive
N/A
Cut-off value applied ≥35 IU/mL ≥30 IU/mL ≥5 IU/mL ≥50 IU/mL N/A
Antigen source SyntheticdsDNA Native calf thymus Synthetic dsDNA
Purified native
dsDNA
Crithidia luciliae
substrate
CIA: chemiluminescent immunoassay; ELISA: enzyme linked immunosorbent assay; ALBIA: addressable laser bead immunoassay; CLIFT: Crithidia luciliae
indirect immunofluorescence test.
2. Materials and Methods
2.1. Sera. In the first part of the study, 161 samples, 61
from patients suffering from SLE and 100 controls, including
Hashimoto’s thyroiditis (𝑛 = 40), rheumatoid arthritis (𝑛 =
40), and blood donors (𝑛 = 20) from apparently healthy
individuals, were tested for anti-dsDNA IgG by QUANTA
Flash dsDNA CIA (Inova Diagnostics, San Diego, CA, USA),
QUANTA Lite dsDNA SC ELISA (Inova Diagnostics Inc.),
BioPlex 2200MFI (Bio-Rad, USA), ImmuLisa dsDNAELISA
(Immco Diagnostics, Buffalo, NY, USA), and NOVA Lite
CLIFT (Inova Diagnostics). A second cohort of 69 SLE
patients was tested by QUANTA Flash dsDNA CIA and
NOVA Lite CLIFT to expand the first part of the study for
these methods. The diagnoses were established as described
in a previous paper before or, if applicable, according to the
standard disease criteria [8].
This study meets and is in compliance with all ethical
standards in medicine, and informed consent was obtained
from all patients according to the Declaration of Helsinki.
2.2. QUANTA Flash dsDNA. The QUANTA Flash dsDNA
(Inova Diagnostics Inc.) assay is a novel CIA that is used on
the BIO-FLASH instrument (Biokit s.a., Barcelona, Spain),
fitted with a luminometer, as well as the hardware and
liquid handling accessories necessary to fully automate the
assay. The principle of the BIO-FLASH system has recently
been described [9, 10]. The QUANTA Flash assay for this
study was developed using synthetic dsDNA (see Table 1)
coupled to the surface of paramagnetic beads. Prior to use,
the lyophilized beads are resuspended using the resuspension
buffer. A patient serum sample is prediluted with the BIO-
FLASH sample buffer in a small disposable plastic cuvette.
Small amounts of the diluted patient serum, the beads, and
the assay buffer are all combined into a second cuvette,
mixed, and then incubated for 9.5 minutes at 37∘C. The
magnetized beads are sedimented using a strong magnet in
the washing station and washed several times followed by
addition of isoluminol conjugated anti-human IgG and again
incubated for 9.5 minutes at 37∘C. The magnetized beads are
sedimented andwashed repeatedly.The isoluminol conjugate
is oxidized when sodium hydroxide solution and peroxide
solutions (triggers) are added to the cuvette, and the flash of
light produced from this reaction is measured as relative light
units (RLUs) by the BIO-FLASH optical system. The RLUs
are proportional to the amount of isoluminol conjugate that is
bound to the human IgG, which is in turn proportional to the
amount of autoantibodies bound to the antigen on the beads.
2.3. BioPlex 2200. BioPlex 2200 (Bio-Rad, Hercules, CA)
system is an automated analyzer that uses multiplex bead
technology (Luminex, Austin, TX, USA) to simultaneously
detect antibodies to several antigens in a single tube. The
BioPlex 2200 ANA Screen is intended for the qualitative
screening of ANA, the quantitative detection of antibody
to dsDNA, and the semiquantitative detection of ten sepa-
rate antibodies (Chromatin, Ribosomal P, SS-A, SS-B, Sm,
SmRNP, RNP, Scl-70, Jo-1, and Centromere B) [11, 12] in
human serum and/or EDTA or heparinized plasma. The
test system is used as an aid in the diagnosis of SARD.
Characteristics of the assay are summarized in Table 1.
2.4. ELISAs (ImmuLisa dsDNA ELISA and QUANTA Lite
dsDNA SC ELISA). Both the ImmuLisa dsDNA (Immco
Diagnostics) and QUANTA Lite dsDNA SC (Inova Diagnos-
tics Inc.) are enzyme linked immunosorbent assays (ELISA)
for the quantitative or semiquantitative detection of IgG
specific for dsDNA in human serum as an aid in the diagnosis
of SLE in conjunction with other laboratory and clinical
findings. Both assays were performed at Inova Diagnostics
according to the direction insert. Characteristics of the assays
are summarized in Table 1.
2.5. NOVA Lite dsDNA Crithidia luciliae (CLIFT). NOVA
Lite dsDNA CLIFT (Inova Diagnostics Inc.) is an indi-
rect immunofluorescence (IIF) assay for the screening and
titration based determination of anti-dsDNA antibodies in
human serum. The NOVA Lite dsDNA CLIFT employs the
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hemoflagellate Crithidia luciliae as a substrate. This single-
cell organism possesses a giant mitochondrion containing a
highly condensed mass of circular dsDNA. The assay was
performed by a single operator using an LED microscope at
Inova Diagnostics according to the direction insert. CLIFT
results were graded from 0 to 4 according to the intensity
(see also direction insert of the kit); 4 is brilliant apple
green fluorescence; 3 is bright apple green fluorescence; 2 is
clearly distinguishable positive fluorescence; 1 is lowest spe-
cific fluorescence that enables the kinetoplast staining to be
clearly differentiated from the background fluorescence; 0 is
negative. Characteristics of the assay are summarized in
Table 1.
2.6. Precision and Linearity Studies. Precision and linearity of
the QUANTA Flash dsDNACIAwere verified by performing
the required testing according to the Clinical and Laboratory
Standards Institute (CLSI) guidelines. For the precision study,
the within-run, between-day, between-run, and total preci-
sion were determined by running two aliquots of the preci-
sion samples twice a day in random order, with a minimum
of 2 hours between each run. The samples were run on the
same instrument for each assay and repeated for at least 20
days, according to CLSI guideline EP5-A2. Linearity testing
was performed according to CLSI guideline EP6-A (volume
23, number 16), which involved diluting several high titer sera
in a serial dilution scheme to span the analytical measuring
range (AMR) for each assay.
2.7. Statistical Analyses. The data were statistically evaluated
using the Analyse-it software (version 1.62; Analyse-it Soft-
ware, Ltd., Leeds, UK). Spearman’s correlation and Cohen’s
kappa agreement test were carried out to analyze the agree-
ment between portions and 𝑃 values < 0.05 were considered
significant. Receiver operating characteristics (ROC) analysis
was used to analyze the discriminatory ability of different
immunoassays. Cluster analysiswas used to illustrate the rela-
tionship between different assays [13] and to display the reac-
tivity pattern of the patients. Hierarchical clustering was per-
formed using average linkage clustering where patient cor-
relation was performed uncentered and the reactivities were
uncentered. For the assays having an equivocal range, all data
was analyzed using the applied cut-offs listed in Table 1, where
the equivocal results were considered positive.
3. Results
3.1. Precision and Linearity. For the precision testing of
QUANTA Flash dsDNA CIA, seven samples ranging from
27.3 to 402.8 IU/mL were tested. For all samples, the within-
run varied between 4.7 and 6.9%, the between-day varied
between 2.3 and 4.0%, and the between-run varied between
0.0 and 4.9%.The total precision for the assay varied between
6.6 and 8.2%. The linearity study showed linearity of the
QUANTA Flash dsDNA CIA from 7.8 to 683.8 IU/mL with
a slope of 1.06 (95% confidence interval 1.04–1.08), a 𝑌-
intercept of −2.0 (−6.9–2.8), and an 𝑅2 of 0.99. QUANTA
Flash dsDNA CIA demonstrated linearity over the entire
AMR.
3.2. Qualitative and Quantitative Agreements between dsDNA
Methods. The overall qualitative agreements varied between
77.0% (NOVA Lite CLIFT versus QUANTA Lite) and 89.4%
(ImmuLisa versus NOVA Lite CLIFT). Kappa agreements
were low ranging from 0.17 to 0.42 (QUANTA Lite and
QUANTA Flash versus BioPlex). Total percent agreement,
kappa values, and Spearman’s rho between dsDNA methods
can be found in Table 2 (Spearman correlation graphs
between dsDNA methods are not shown).
3.3. Clinical Performance of Five Anti-dsDNA Assays. The
clinical sensitivities at the recommended cut-off were 8.2%
(95% confidence interval, CI 2.7–18.1%) for NOVA Lite
CLIFT, 26.2% (95% CI 15.8–39.1%) for ImmuLisa, 39.3%
(95% CI 27.2–52.7%) for QUANTA Flash, 44.3% (95% CI
31.5–57.6%) for BioPlex, and 54.1% (95% CI 40.8–66.9) for
QUANTA Lite. The clinical specificities at the recommended
cut-off were 100.0% (95% CI 96.4–100.0%) for NOVA Lite
CLIFT, 96.0% (95% CI 90.1–98.9%) for ImmuLisa, 96.0%
(95% CI 90.1–98.9%) for QUANTA Flash, 88.0% (95% CI
80.0–93.6%) for BioPlex, and 91.0% (95% CI 83.6–95.8%) for
QUANTA Lite. When the sensitivities were compared at a
specificity of 94.0%, the values ranged between 8.2% (95%
CI 2.7–18.1%) for CLIFT and 52.5% (95% CI 39.3–65.4%) for
QUANTA Flash dsDNA CIA. Sensitivities and specificities
as well as positive and negative likelihoods ratios (LR) and
area under the curve (AUC) values for all assays are shown
in Table 3. The odds ratio (LR+/LR−) for dsDNA methods
varied between 5.9 (BioPlex) and 15.6 (QUANTA Flash).
Comparative ROC curve analysis among SLE patients (𝑛 =
61) and disease controls (𝑛 = 100) for five anti-dsDNA
antibody assays showed significantly different AUC values.
QUANTA Flash and QUANTA Lite had the highest AUC
values which were significantly higher (𝑃 < 0.05) than the
AUC values of the other assays (see Figure 1).
3.4. Cluster Analysis. To illustrate the reactivity of various
assays in relation to the diagnosis, we performed a cluster
analysis. The cluster analysis shows that the majority of SLE
patients have multiple positive results (Figure 2). Some of the
controls also show positive results by different methods. The
dendrogram shows the QUANTA Lite dsDNA SC clusters
closest to the diagnosis of SLE followed by QUANTA Flash
and BioPlex 2200.
3.5. Comparison of Anti-dsDNA Assays with CLIFT and
ExtendedClinical Evaluation forQUANTAFlash dsDNA. The
CLIFT is often used as a confirmatory assay. Consequently,
we used the CLIFT results (positive versus negative) as the
reference and analyzed the utility of the other assays tomatch
the sensitivity and specificity of theCLIFT.All CLIFTpositive
samples were also positive by all fourmethods, except for one
sample thatwasmissed by the ImmuLisa. ROCanalysis (ROC
curve not shown) of the four anti-dsDNA antibody assays
compared to CLIFT resulted in AUC values of 0.93 (95% CI
0.85–1.00) for BioPlex, 0.94 (95%CI 0.88–1.00) for ImmuLisa,
0.95 (95% CI 0.91–0.99) for QUANTA Lite, and 0.97 (95%
CI 0.94–0.99) for QUANTA Flash. A cut-off of 106.7 IU/mL
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Table 2: Qualitative and quantitative agreements between anti-dsDNA antibody assays.
NOVA Lite
dsDNA CLIFT
QUANTA Flash
dsDNA
QUANTA Lite
dsDNA SC
BioPlex 2200
dsDNA
ImmuLisa
dsDNA
QUANTA Flash
dsDNA
85.7 (79.3–90.7)
kappa = 0.26
(0.08–0.45)
78.9 (71.8–84.9)
kappa = 0.39
(0.22–0.55)
80.7 (73.8–86.5)
kappa = 0.42
(0.25–0.59)
83.9 (77.2–89.2)
kappa = 0.37
(0.17–0.56)
N/A∗
rho = 0.58
(0.46–0.67)
P < 0.0001
rho = 0.46
(0.33–0.57)
P < 0.0001
rho = 0.34
(0.19–0.47)
P < 0.0001
QUANTA Lite
dsDNA SC
77.0 (69.7–83.3)
kappa = 0.17
(0.04–0.30)
78.9 (71.8–84.9)
kappa = 0.39
(0.22–0.55)
78.3 (71.1–84.4)
kappa = 0.42
(0.26–0.58)
80.1 (73.1–86.0)
kappa = 0.38
(0.22–0.54)
N/A∗
rho = 0.58
(0.46–0.67)
P < 0.0001
rho = 0.43
(0.30–0.55)
P < 0.0001
rho = 0.39
(0.25–0.51)
P < 0.0001
BioPlex 2200
dsDNA
78.9 (71.8–84.9)
kappa = 0.18
(0.04–0.32)
80.7 (73.8–86.5)
kappa = 0.42
(0.25–0.59)
78.3 (71.1–84.4)
kappa = 0.42
(0.26–0.58)
80.7 (73.8–86.5)
kappa = 0.37
(0.20–0.54)
N/A∗
rho = 0.46
(0.33–0.57)
P < 0.0001
rho = 0.43
(0.30–0.55)
P < 0.0001
rho = 0.30
(0.16–0.44)
P < 0.0001
ImmuLisa
dsDNA
89.4% (83.6–93.7)
kappa = 0.28
(0.05–0.51)
83.9 (77.2–89.2)
kappa = 0.37
(0.17–0.56)
80.1 (73.1–86.0)
kappa = 0.38
(0.22–0.54)
80.7 (73.8–86.5 )
kappa = 0.37
(0.20–0.54)
N/A∗
rho = 0.34
(0.19–0.47)
P < 0.0001
rho = 0.39
(0.25–0.51)
P < 0.0001
rho = 0.30
(0.16–0.44)
P < 0.0001
Note: total qualitative agreements are given in percent, followed by kappa statistics and Spearman’s rho values (95% confidence intervals are provided in the
parentheses). ∗NOVA Lite CLIFT was excluded from the analysis since it is a semiquantitative assay where grading values (0 to 4) are given by the operator.
Table 3: Clinical performance characteristics for anti-dsDNA antibody assays.
QUANTA Flash
dsDNA
QUANTA Lite
dsDNA SC
BioPlex 2200
dsDNA
ImmuLisa
dsDNA
NOVA Lite
dsDNA
Manufacturer’s cut-off
used, where equivocal
results are considered
positive
≥35 IU/mL ≥30 IU/mL ≥5 IU/mL ≥50 IU/mL N/A
Sensitivity in SLE%
(95% CI) 39.3 (27.2–52.7) 54.1 (40.8–66.9) 44.3 (31.5–57.6) 26.2 (15.8–39.1) 8.2 (2.7–18.1)
Specificity %
(95% CI) 96.0 (90.1–98.9) 91.0 (83.6–95.8) 88.0 (80.0–93.6) 96.0 (90.1–98.9)
100.0
(96.4–100.0)
LR+ 9.84 6.01 3.69 6.56 +∞
LR− 0.63 0.50 0.63 0.77 0.92
Odds ratio 15.6 12.0 5.9 8.5 N/A
AUC (95% CI) 0.79 (0.72–0.87) 0.90 (0.86–0.95) 0.68 (0.60–0.77) 0.61 (0.52–0.71) 0.54 (0.51–0.58)
Cut-off used at 94.0%
specificity ≥27.5 IU/mL ≥49.6 IU/mL ≥12 IU/mL ≥41.9 IU/mL N/A
Sensitivity in SLE%
at 94.0% specificity (95%
CI)
52.5 (39.3–65.4) 45.9 (33.1–59.2) 21.3 (11.9–33.7) 27.9 (17.1–40.8) N/A
AUC: area under the curve; LR: likelihood ratio; CI: confidence interval.
for QUANTA Flash dsDNA would result in an optimal
agreement to CLIFT, with a positive agreement of 100.0%
(95% CI 47.8–100.0%), negative agreement of 95.5% (95% CI
91.0–98.2%), total agreement of 95.7% (95% CI 91.2–98.2%),
and kappa = 0.57 (95% CI 0.29–0.85). To further validate
the good agreement between QUANTA Flash dsDNA and
CLIFT, additional SLE patients (𝑛 = 69, Inova Diagnostics
serum bank) tested by both methods were added to the
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Figure 1: Comparison of different assays for the detection of anti-dsDNA antibodies using receiver operating characteristics (ROC) analysis.
The ROC curves show the discrimination between SLE patients (𝑛 = 61) and controls (𝑛 = 100) using different assays. Note: the NOVA Lite
CLIFT assay is a semiquantitative assay (grades 0 to 4 were given by operator).
SLE Controls
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Figure 2: Supervised cluster analysis of the results. Supervised centered cluster analysis according to disease cohort (SLE versus controls) is
shown.The dendrogram shows the QUANTA Lite dsDNA SC clusters closest to the diagnosis of SLE followed byQUANTA Flash and BioPlex
2200. SLE: systemic lupus erythematosus.
study population. ROC analysis of the clinical performance
for NOVA Lite CLIFT and QUANTA Flash dsDNA among
the new study population (SLE = 130, controls = 100) can
be found in Figure 3. ROC analysis for the agreement of
QUANTA Flash dsDNA results to NOVA Lite CLIFT results
can be found in Figure 4.
4. Discussion
Anti-dsDNA antibodies are a hallmark in the diagnosis
of SLE and are part of the classification criteria [2]. Dur-
ing the last decades, several novel technologies have been
developed for anti-dsDNA antibody detection including the
conventional ELISA and, more recently, line immunoassays
(LIA), CIA, and multiplex assays [11, 12]. As ELISAs are only
moderately fast with assay times between 1.5 and 3 hours,
the focus has lately shifted towards a decrease in assay time
and ease of use. Despite significant technological advances,
controversies persist on the method of choice for the
detection of these antibodies [4, 14].TheBioPlex 2200 dsDNA
assay has been compared to other assays (Farr and Farrzyme)
in a recent study [15]. Additionally, several studies used
the BioPlex 2200 dsDNA assay as the only method for the
detection of anti-dsDNA antibodies [16, 17]. The sensitivity
in our cohort (44.3%) was very similar to the data (40%)
presented by Op De Bee´ck et al. [16] but significantly lower
than previous results [18]. The CLIFT assay is an IIF test
based on the hemoflagellateCrithidia luciliae as the substrate.
Commercial assays are offered by various companies. Various
commercial ELISA tests are available through numerous
companies. Although based on the same technology, poor
agreement can be observed, as seen in previous studies [14,
15, 19, 20]. Similar to the sensitivity observed for BioPlex 2200
dsDNA in this study, the sensitivity in SLE found for the two
ELISAs was lower than previous studies [21, 22], indicating
that the SLE sample population for this study could be the
reason. Lastly, the Farr assay has been considered as the “gold
standard” for the detection of anti-dsDNAantibodies [4, 6, 7].
However, not in all studies, the Farr assay was superior to
other methods for the detection of anti-dsDNA antibodies
and the discrimination of SLE and controls [14]. Additionally,
in many countries, laboratories are switching from the Farr
assay to fully automated solutions, which is largely due to
the radioactive nature of the Farr assay [4, 5]. Therefore,
considering that newer fully automated technologies are
available, it is important to evaluate these methods as viable
6 Journal of Immunology Research
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Figure 3: Comparison of NOVALite CLIFT andQUANTAFlash dsDNA for the detection of anti-dsDNA antibodies using receiver operating
characteristics (ROC) analysis. The ROC curves show the discrimination between SLE patients (𝑛 = 130) and controls (𝑛 = 100). Note: the
NOVA Lite CLIFT is a semiquantitative assay (grades 0 to 4 were given by operator).
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Figure 4: Receiver operating characteristics (ROC) analysis of QUANTA Flash dsDNA compared to CLIFT positive (𝑛 = 35) and
negative (𝑛 = 195) samples. Different cut-offs are shown to demonstrate the optimal agreements. Note: equivocal range determined by
the manufacturer is along the 80.0% positive agreement (green highlight). PPA: positive percent agreement; TPA: total percent agreement.
alternatives as the Farr assay becomes less popular. Some
studies also investigated the impact of the antigen source
on the performance of anti-dsDNA antibody assays. Since
this study compares not only different technologies but also
methods with different antigen sources, it is unclear if antigen
source is a contributor to the variability in the results. This
is the first study on QUANTA Flash dsDNA, a novel CIA
for detection of anti-dsDNA antibodies. Like other assays on
the BIO-FLASH [9, 23, 24], the QUANTA Flash dsDNA CIA
delivers quantitative results with high precision and linearity
in as little as 30 minutes. The QUANTA Flash dsDNA
CIA showed lower sensitivity compared to the QUANTA
Lite dsDNA ELISA (39.3% versus 54.1%) but had a higher
specificity (96.0% versus 91.0%) and a higher odds ratio
compared to the other methods. By setting the specificity to
the clinically relevant level of 94.0% for all dsDNA methods,
QUANTA Flash dsDNA CIA achieved the highest sensitivity
(52.5%). Since theCLIFT assay is often used as a confirmatory
test for the detection of anti-dsDNA antibodies, we aimed
to analyze the possibility to use higher cut-off values for
QUANTA Flash dsDNA to increase the agreement to CLIFT.
Using a cut-off of 106.7 IU/mL, the agreement increased to
95.7%. The extended study between QUANTA Flash dsDNA
CIA and NOVA Lite CLIFT with additional SLE samples
resulted in good agreement between methods around the
manufacturer’s cut-off for QUANTA Flash dsDNA. Figure 4
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displays the agreement of QUANTA Flash dsDNA to CLIFT
at various cut-offs, which demonstrates the potential tomatch
the samples positive by CLIFT. This finding is promising
that, using the QUANTA Flash dsDNA, confirmation testing
might become unnecessary. However, future studies are
needed to confirm this observation. A limitation of our
study is the number of SLE patients and controls, but the
strength of the study is the number of technologies analyzed.
However, despite the small cohort of patients, we found
significant differences between the assays and confirmed the
lack of standardization [19, 20]. Another shortcoming is
the exclusion of the Farr assay from our study due to the
lack of access to the technology. At our facility, assays with
radioactive materials cannot be performed and the sample
volumes were too low to send out samples for testing. On
the other hand, we included five methods for the detection of
anti-dsDNA antibodies. Further studies with larger cohorts
are needed to contribute to the understanding of how anti-
dsDNA antibody assays perform and correlate.
5. Conclusion
Significant variations among anti-dsDNA antibody assays
were observed confirming the lack of standardization.
QUANTA Flash dsDNA CIA provides an optimal combina-
tion of sensitivity and specificity for the diagnosis of SLE.
Future studies with larger sample populations are needed to
confirm the clinical performance and agreement to CLIFT.
Abbreviations
AUC: Area under the curve
AMR: Analytical measuring range
CIA: Chemiluminescent immunoassay
CLIFT: Crithidia luciliae indirect
immunofluorescence test
CTD: Connective tissue disease
ELISA: Enzyme-linked immunosorbent assay
LIA: Line immunoassays
MFI: Multiplex flow immunoassay
ROC: Receiver-operating characteristics
SARD: Systemic autoimmune rheumatic
disease
SLE: Systemic lupus erythematosus.
Highlights
(i) Significant variations among dsDNA methods were
observed.
(ii) QUANTA Flash dsDNA showed good analytical and
clinical performance in this study.
(iii) Standardization of anti-dsDNA assays still requires
improvements.
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